My main interest is to work on developing gene therapy using promising virus vectors.
During my phD and master studies, I studied the behavior of a new pharmacological tool, a GPCR insensible to its endogenous ligand. By viral vector, we introduced this gene to protect dopaminergic neurons in an in vitro neurodegenerative model of Parkinson's disease.
My postdoctoral interest is to extend my competence in in vivo therapeutic studies.
The aim of our current project is to develop a crumbs (Crb1) human gene therapy. Mutations in this protein lead to retinitis pigmentosa (RP) and Leber congenital Amaurosis (LCA). Using AAV particles, restoring Crb1expression in Muller glial cells will protect photoreceptors degeneration in Crb1 deficient mice and humans.